Amicus Therapeutics (FOLD) 6.00 $FOLD
Amicus Therapeutics Expands Biologics Pipeline with New Preclinical Program for Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency
GlobeNewswire - Wed Jul 06, 3:01PM CDT
Amicus Therapeutics, Inc. (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, has expanded its biologics pipeline with a new preclinical program for cyclin-dependent kinase-like 5 (CDKL5) deficiency, a rare and devastating genetic neurological disease for which there is no currently approved treatment. Signs and symptoms typically begin with persistent, spontaneous seizures in infancy followed by severe delays in neurological development.
FOLD: 6.00 (-0.17)
Dr. Ron Nardi Joins viDA Therapeutics Science Advisory Board
CNW Group - Wed Jun 15, 9:59AM CDT
viDA Therapeutics, Inc. (viDA) announced today that Dr. Ron Nardi has been appointed to the Science Advisory Board (SAB).
FOLD: 6.00 (-0.17)
Amicus Therapeutics Appoints Craig A. Wheeler to Board of Directors
GlobeNewswire - Fri Jun 10, 6:30AM CDT
Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, today announced the election and appointment of Craig A. Wheeler to its Board of Directors, effective immediately. In addition, Amicus announced that John F. Crowley, Margaret G. McGlynn, Michael G. Raab, and Glenn P. Sblendorio were re-elected at the 2016 Annual Meeting of Stockholders.
FOLD: 6.00 (-0.17)
Bradley Campbell, President and COO of Amicus Therapeutics, elected to Progenics Board of Directors
GlobeNewswire - Thu Jun 09, 7:00AM CDT
Progenics Pharmaceuticals, Inc. (Nasdaq
GNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, today announced the election of Bradley Campbell to the Company's Board of Directors. Mr. Campbell brings to Progenics extensive experience in the biopharmaceutical industry, with particular expertise in the areas of corporate strategy, commercial operations and planning, business development and sales and marketing. He currently serves as President and Chief Operating Officer of Amicus Therapeutics, a biotechnology company focused on the development of therapies for a broad range of rare and orphan diseases.
PGNX: 5.47 (+0.03), FOLD: 6.00 (-0.17)
Amicus Therapeutics to Present at the Goldman Sachs 37th Annual Global Healthcare Conference
GlobeNewswire - Wed Jun 01, 6:30AM CDT
Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a corporate overview and fireside chat at the Goldman Sachs 37 Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Tuesday, June 7, 2016 at 2:40 p.m. PT.
FOLD: 6.00 (-0.17)
Amicus Therapeutics Announces European Commission Approval for Galafold(TM) (Migalastat) in Patients with Fabry Disease in European Union
GlobeNewswire - Tue May 31, 6:30AM CDT
Launch has Begun in Germany
FOLD: 6.00 (-0.17)
Amicus Therapeutics to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
GlobeNewswire - Thu May 05, 6:30AM CDT
Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that Chip Baird, Chief Financial Officer, will present a corporate overview at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas, NV on Wednesday, May 11, 2016 at 4:20 p.m. PT.
FOLD: 6.00 (-0.17)
Amicus Therapeutics reports 1Q loss
Automated Insights - Tue May 03, 7:01AM CDT
CRANBURY, N.J. (AP) _ Amicus Therapeutics Inc. (FOLD) on Tuesday reported a loss of $43.7 million in its first quarter.
FOLD: 6.00 (-0.17)
Amicus Therapeutics Announces First Quarter 2016 Financial Results and Corporate Updates
GlobeNewswire - Tue May 03, 6:00AM CDT
Positive CHMP Opinion for Broad Label of Migalastat for Fabry Disease in Patients with Amenable Mutations
FOLD: 6.00 (-0.17)
Merck (MRK) Q1 Earnings: Can the Stock Pull a Surprise?
Arpita Dutt - Zacks Investment Research - Mon May 02, 10:12AM CDT
Will Merck (MRK) maintain its impressive track record and deliver a positive earnings surprise this quarter as well?
MRK: 59.35 (+0.57), BIND: 0.56 (+0.01), CHMA: 2.98 (+0.10), FOLD: 6.00 (-0.17)
Ligand (LGND) Q1 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Mon May 02, 10:09AM CDT
Will Ligand (LGND) pull a surprise and surpass expectations in the first quarter as well?
LGND: 125.86 (+2.13), SPPI: 6.75 (-0.04), BIND: 0.56 (+0.01), FOLD: 6.00 (-0.17)
Amicus Therapeutics to Announce First Quarter 2016 Financial Results on May 3, 2016
GlobeNewswire - Tue Apr 26, 6:30AM CDT
Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, today announced a conference call and live audio webcast on Tuesday, May 3, 2016 at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2016.
FOLD: 6.00 (-0.17)
Amicus Therapeutics Set to Possibly Rebound After Yesterday's Selloff of 2.00%
Comtex SmarTrend(R) - Fri Apr 15, 3:41PM CDT
Amicus Therapeutics (NASDAQ:FOLD) traded in a range yesterday that spanned from a low of $7.76 to a high of $8.00. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $7.83 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
FOLD: 6.00 (-0.17)
What Caused Amicus Therapeutics Shares To Skyrocket 23% Last Month
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 12, 3:41PM CDT
SOURCE: AMICUS THERAPEUTICS What: After reporting additional late stage trial data and ahead of learning that a key European advisory committee had voted in support of its lead drug, shares of Amicus Therapeutics shot 23.4% higher in March,...
SHPG: 188.21 (-1.31), FOLD: 6.00 (-0.17)
22.5% Return Seen to Date on SmarTrend Amicus Therapeutics Call (FOLD)
Comtex SmarTrend(R) - Mon Apr 04, 12:44PM CDT
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on February 22nd, 2016 at $7.08. In approximately 1 month, Amicus Therapeutics has returned 22.46% as of today's recent price of $8.67.
FOLD: 6.00 (-0.17)
Amicus Therapeutics Receives Positive CHMP Opinion for Approval of Migalastat in Patients with Fabry Disease in European Union
GlobeNewswire - Fri Apr 01, 10:43AM CDT
Broad Label for All Fabry Patients with an Amenable Genetic Mutation
FOLD: 6.00 (-0.17)
Look for Shares of Amicus Therapeutics to Potentially Pullback after Yesterday's 8.39% Rise
Comtex SmarTrend(R) - Thu Mar 31, 3:12PM CDT
Amicus Therapeutics (NASDAQ:FOLD) traded in a range yesterday that spanned from a low of $7.95 to a high of $8.74. Yesterday, the shares gained 8.4%, which took the trading range above the 3-day high of $8.58 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
FOLD: 6.00 (-0.17)
viDA Therapeutics Inc. Appoints Orphan Product Executive to Board of Directors
CNW Group - Wed Mar 30, 2:38AM CDT
viDA Therapeutics, Inc. (viDA) announced today that Dr. Robert P. Ryan has been appointed to its Board of Directors.
FOLD: 6.00 (-0.17)
Amicus Therapeutics Announces Expanded Access Program for Migalastat
GlobeNewswire - Tue Mar 22, 6:30AM CDT
Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, has initiated a reimbursed expanded access program (EAP) to provide Fabry patients who have amenable mutations with access to migalastat. The EAP will be implemented in certain territories where reimbursement can be secured prior to marketing authorization and commercial availability, beginning in France.
FOLD: 6.00 (-0.17)
Amicus Therapeutics Expands Biologics Pipeline with New Preclinical Program for Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency
GlobeNewswire - Wed Jul 06, 3:01PM CDT
Amicus Therapeutics, Inc. (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, has expanded its biologics pipeline with a new preclinical program for cyclin-dependent kinase-like 5 (CDKL5) deficiency, a rare and devastating genetic neurological disease for which there is no currently approved treatment. Signs and symptoms typically begin with persistent, spontaneous seizures in infancy followed by severe delays in neurological development.
FOLD: 6.00 (-0.17)
Dr. Ron Nardi Joins viDA Therapeutics Science Advisory Board
CNW Group - Wed Jun 15, 9:59AM CDT
viDA Therapeutics, Inc. (viDA) announced today that Dr. Ron Nardi has been appointed to the Science Advisory Board (SAB).
FOLD: 6.00 (-0.17)
Amicus Therapeutics Appoints Craig A. Wheeler to Board of Directors
GlobeNewswire - Fri Jun 10, 6:30AM CDT
Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, today announced the election and appointment of Craig A. Wheeler to its Board of Directors, effective immediately. In addition, Amicus announced that John F. Crowley, Margaret G. McGlynn, Michael G. Raab, and Glenn P. Sblendorio were re-elected at the 2016 Annual Meeting of Stockholders.
FOLD: 6.00 (-0.17)
Bradley Campbell, President and COO of Amicus Therapeutics, elected to Progenics Board of Directors
GlobeNewswire - Thu Jun 09, 7:00AM CDT
Progenics Pharmaceuticals, Inc. (Nasdaq
GNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, today announced the election of Bradley Campbell to the Company's Board of Directors. Mr. Campbell brings to Progenics extensive experience in the biopharmaceutical industry, with particular expertise in the areas of corporate strategy, commercial operations and planning, business development and sales and marketing. He currently serves as President and Chief Operating Officer of Amicus Therapeutics, a biotechnology company focused on the development of therapies for a broad range of rare and orphan diseases. PGNX: 5.47 (+0.03), FOLD: 6.00 (-0.17)
Amicus Therapeutics to Present at the Goldman Sachs 37th Annual Global Healthcare Conference
GlobeNewswire - Wed Jun 01, 6:30AM CDT
Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a corporate overview and fireside chat at the Goldman Sachs 37 Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Tuesday, June 7, 2016 at 2:40 p.m. PT.
FOLD: 6.00 (-0.17)
Amicus Therapeutics Announces European Commission Approval for Galafold(TM) (Migalastat) in Patients with Fabry Disease in European Union
GlobeNewswire - Tue May 31, 6:30AM CDT
Launch has Begun in Germany
FOLD: 6.00 (-0.17)
Amicus Therapeutics to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
GlobeNewswire - Thu May 05, 6:30AM CDT
Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that Chip Baird, Chief Financial Officer, will present a corporate overview at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas, NV on Wednesday, May 11, 2016 at 4:20 p.m. PT.
FOLD: 6.00 (-0.17)
Amicus Therapeutics reports 1Q loss
Automated Insights - Tue May 03, 7:01AM CDT
CRANBURY, N.J. (AP) _ Amicus Therapeutics Inc. (FOLD) on Tuesday reported a loss of $43.7 million in its first quarter.
FOLD: 6.00 (-0.17)
Amicus Therapeutics Announces First Quarter 2016 Financial Results and Corporate Updates
GlobeNewswire - Tue May 03, 6:00AM CDT
Positive CHMP Opinion for Broad Label of Migalastat for Fabry Disease in Patients with Amenable Mutations
FOLD: 6.00 (-0.17)
Merck (MRK) Q1 Earnings: Can the Stock Pull a Surprise?
Arpita Dutt - Zacks Investment Research - Mon May 02, 10:12AM CDT
Will Merck (MRK) maintain its impressive track record and deliver a positive earnings surprise this quarter as well?
MRK: 59.35 (+0.57), BIND: 0.56 (+0.01), CHMA: 2.98 (+0.10), FOLD: 6.00 (-0.17)
Ligand (LGND) Q1 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Mon May 02, 10:09AM CDT
Will Ligand (LGND) pull a surprise and surpass expectations in the first quarter as well?
LGND: 125.86 (+2.13), SPPI: 6.75 (-0.04), BIND: 0.56 (+0.01), FOLD: 6.00 (-0.17)
Amicus Therapeutics to Announce First Quarter 2016 Financial Results on May 3, 2016
GlobeNewswire - Tue Apr 26, 6:30AM CDT
Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, today announced a conference call and live audio webcast on Tuesday, May 3, 2016 at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2016.
FOLD: 6.00 (-0.17)
Amicus Therapeutics Set to Possibly Rebound After Yesterday's Selloff of 2.00%
Comtex SmarTrend(R) - Fri Apr 15, 3:41PM CDT
Amicus Therapeutics (NASDAQ:FOLD) traded in a range yesterday that spanned from a low of $7.76 to a high of $8.00. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $7.83 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
FOLD: 6.00 (-0.17)
What Caused Amicus Therapeutics Shares To Skyrocket 23% Last Month
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 12, 3:41PM CDT
SOURCE: AMICUS THERAPEUTICS What: After reporting additional late stage trial data and ahead of learning that a key European advisory committee had voted in support of its lead drug, shares of Amicus Therapeutics shot 23.4% higher in March,...
SHPG: 188.21 (-1.31), FOLD: 6.00 (-0.17)
22.5% Return Seen to Date on SmarTrend Amicus Therapeutics Call (FOLD)
Comtex SmarTrend(R) - Mon Apr 04, 12:44PM CDT
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on February 22nd, 2016 at $7.08. In approximately 1 month, Amicus Therapeutics has returned 22.46% as of today's recent price of $8.67.
FOLD: 6.00 (-0.17)
Amicus Therapeutics Receives Positive CHMP Opinion for Approval of Migalastat in Patients with Fabry Disease in European Union
GlobeNewswire - Fri Apr 01, 10:43AM CDT
Broad Label for All Fabry Patients with an Amenable Genetic Mutation
FOLD: 6.00 (-0.17)
Look for Shares of Amicus Therapeutics to Potentially Pullback after Yesterday's 8.39% Rise
Comtex SmarTrend(R) - Thu Mar 31, 3:12PM CDT
Amicus Therapeutics (NASDAQ:FOLD) traded in a range yesterday that spanned from a low of $7.95 to a high of $8.74. Yesterday, the shares gained 8.4%, which took the trading range above the 3-day high of $8.58 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
FOLD: 6.00 (-0.17)
viDA Therapeutics Inc. Appoints Orphan Product Executive to Board of Directors
CNW Group - Wed Mar 30, 2:38AM CDT
viDA Therapeutics, Inc. (viDA) announced today that Dr. Robert P. Ryan has been appointed to its Board of Directors.
FOLD: 6.00 (-0.17)
Amicus Therapeutics Announces Expanded Access Program for Migalastat
GlobeNewswire - Tue Mar 22, 6:30AM CDT
Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, has initiated a reimbursed expanded access program (EAP) to provide Fabry patients who have amenable mutations with access to migalastat. The EAP will be implemented in certain territories where reimbursement can be secured prior to marketing authorization and commercial availability, beginning in France.
FOLD: 6.00 (-0.17)
